Abstract

Gaining Access to Investigational Drug for Treatment: An Investigational New Drug Application Primer

Author(s): Kramer Mark A, Grilley Bambi J

Issue: Jul/Aug 2002 - Compounding for BHRT and Legal and Regulatory Issues

View All Articles in Issue

Page(s): 271-273

Download in electronic PDF format for $75

Abstract

Related Keywords

Related Categories

Printer-Friendly Version

Related Articles from IJPC

Issue/Page View/Buy	Title/Author (Click for Abstract / Details / Purchase)
Jul/Aug 2002 Pg. 271-273	Gaining Access to Investigational Drug for Treatment: An Investigational New Drug Application Primer Author(s): Kramer Mark A, Grilley Bambi J
Jan/Feb 2020 Pg. 30-36	Quality Control: Personal Protective Equipment for Use When Handling Hazardous Drugs Author(s): Dillon L R
Sep/Oct 2017 Pg. 356	PreScription: 2017 Pharmacy Compounding Issues: The U.S. Food and Drug Administration, Harzardous Drugs, and Wasted Drugs Author(s): Allen Loyd V Jr
Mar/Apr 2018 Pg. 108-121	Personalized Medicine and Customized Drug Delivery Systems: The New Trend of Drug Delivery and Disease Management Author(s): Soni Abhishek, Gowthamarajan Kuppusamy, Radhakrishnan Arun
Sep/Oct 2009 Pg. 400-403	Efforts to Combat Prescription Drug Abuse Should Not Limit Access to Compounded Pain Medications Author(s): Gilbert John A
Nov/Dec 2011 Pg. 526-527	PostScription: Drug Disposal: Compounding Pharmacists' Involvement in the Prevention of Prescription Drug Misuse and Abuse Author(s): Williams LaVonn A
May/Jun 2016 Pg. 202-206	Does Your Drug Expertise Include Clinical Pharmaceutics? Author(s): Newton David W
Jul/Aug 2007 Pg. 350-351	PostScription: Thousands of Unapproved New Drugs are on the U.S. Market, Part 1 Author(s): Allen Loyd V Jr
Jan/Feb 2008 Pg. 38-47 View Sample	Disposing of Expired Drugs and Chemicals: New Options for Compounders Author(s): Vail Jane
Jul/Aug 2022 Pg. 298-301	The Role of Compounding Pharmacists During Drug Shortages Author(s): Ofei Kelvin
Sep/Oct 2021 Pg. 358-362	Determining Whether a Substance is Legal to Compound with Under Section 503A of the FDCA Author(s): Cabaleiro Joe
Sep/Oct 2015 Pg. 377-380	The Evolution of 21 CFR Parts 210 & 211 for Drug Compounders: An Unspoken Opportunity for Pharmacists Author(s): Parks Kenneth Chase, Bernard Brian, Cogdill Christopher Blake
Jul/Aug 2016 Pg. 351 View Sample	Discrepancies in the Law and the U.S. Food and Drug Administration Pharmacy Compounding Compliance Policy Guidelines Author(s): Allen Loyd V Jr
Mar/Apr 2011 Pg. 92	PreScription: Discontinued Drugs and Drug Shortages Author(s): Allen Loyd V Jr
Jul/Aug 2012 Pg. 294-298	Drug Shortages & Discontinued Drugs: The Effects on Patients and Healthcare Providers Author(s): Allen Loyd V Jr, Williams LaVonn A
Nov/Dec 2012 Pg. 456-460	Drug Shortage Compounding: The Only Safe Medication Source in a Time of Crisis Author(s): Lyon Joanna
Jan/Feb 2023 Pg. 4	PreScription: New Drug Approvals 2022 and Compounding Opportunities Author(s): Allen Loyd V Jr
Sep/Oct 2007 Pg. 438-439	PostScription: Thousands of Unapproved New Drugs are on the U.S. Market, Part 2 Author(s): Allen Loyd V Jr
Nov/Dec 2003 Pg. 436-439	Compounding for Investigational Studies: The Experience of Ken Hughes, RPh Author(s): Allen Loyd V Jr
Mar/Apr 2015 Pg. 104-106	Standing Together Fixing the Drug Quality and Security Act Author(s): Miller David G